Tiziana Life Sciences PLC Operating Income 2011-2026 | TLSA

Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.

Formula

Operating profit = Revenue – Operating expenses

Features of the metric

Evaluates business efficiency
Shows how well the company controls its production and administrative costs.
Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies.
Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.

If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.

Annual Operating Income Tiziana Life Sciences PLC

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-	-	-	-27.4 M	-28 M	-9.92 M	-9.87 M	-10.5 M	-9.88 M	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
-9.87 M	-28 M	-15.9 M

Operating Income of other stocks in the Biotechnology industry

Issuer	Operating Income	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	-508 M	-	2.43 %	$ 254 M	Germany
Amgen AMGN	9.08 B	$ 350.62	0.81 %	$ 189 B	USA
Heron Therapeutics HRTX	-2.54 M	$ 0.8	2.35 %	$ 133 M	USA
Altimmune ALT	-94.5 M	$ 3.46	3.44 %	$ 305 M	USA
Genfit SA GNFT	31.8 M	-	2.54 %	$ 160 B	France
Biophytis SA BPTS	-26.8 M	-	-13.47 %	$ 169 M	France
Ascendis Pharma A/S ASND	-452 M	$ 219.42	-1.11 %	$ 5 B	Danmark
Midatech Pharma plc MTP	-7 M	-	-18.52 %	$ 27.3 M	Britain
Applied Genetic Technologies Corporation AGTC	-17.7 M	-	-	$ 26.5 M	USA
ARCA biopharma ABIO	-88.1 M	-	1052.0 %	$ 415 M	USA
Aeterna Zentaris AEZS	-8.67 M	-	5.93 %	$ 314 M	Canada
Incyte Corporation INCY	1.51 B	$ 90.74	-0.04 %	$ 17.7 B	USA
AgeX Therapeutics AGE	-9.89 M	-	-10.17 %	$ 12.2 K	USA
Acorda Therapeutics ACOR	-265 M	-	-24.86 %	$ 820 K	USA
Albireo Pharma ALBO	-123 M	-	-0.23 %	$ 916 M	USA
Inovio Pharmaceuticals INO	-144 M	$ 1.62	2.22 %	$ 35.9 M	USA
Aileron Therapeutics ALRN	-65.1 M	-	10.36 %	$ 9.8 M	USA
Acasti Pharma ACST	-16.7 M	-	4.01 %	$ 150 M	Canada
Avenue Therapeutics ATXI	-11.3 M	-	-52.27 %	$ 4.45 M	USA
Adverum Biotechnologies ADVM	-139 M	-	-	$ 86.2 M	USA
Acer Therapeutics ACER	-24.6 M	-	2.71 %	$ 14 M	USA
Advaxis ADXS	-36.3 M	-	-9.65 %	$ 45.9 M	USA
Ayala Pharmaceuticals AYLA	-37.5 M	-	-	$ 7.46 M	Israel
Cullinan Management CGEM	-242 M	$ 12.92	1.41 %	$ 778 M	USA
Inventiva S.A. IVA	-52.1 M	$ 6.13	6.06 %	$ 138 M	France
BioDelivery Sciences International BDSI	37.1 M	-	-4.8 %	$ 255 M	USA
BeiGene, Ltd. BGNE	447 M	-	0.49 %	$ 251 B	Cayman-islands
KalVista Pharmaceuticals KALV	-188 M	$ 16.76	-1.41 %	$ 832 M	Britain
Calithera Biosciences CALA	-115 M	-	-10.95 %	$ 876 K	USA
Cara Therapeutics CARA	-121 M	-	-3.03 %	$ 260 M	USA
ChemoCentryx CCXI	-130 M	-	-	$ 3.74 B	USA
Bellerophon Therapeutics BLPH	-22.4 M	-	-74.18 %	$ 955 K	USA
Kamada Ltd. KMDA	-696 K	$ 8.23	-0.24 %	$ 260 M	Israel
Checkpoint Therapeutics CKPT	-56.2 M	-	-	$ 169 M	USA
Karyopharm Therapeutics KPTI	-119 M	$ 7.06	-7.47 %	$ 860 K	USA
Clovis Oncology CLVS	-226 M	-	-7.23 %	$ 13 M	USA
Keros Therapeutics KROS	67.6 M	$ 11.27	2.83 %	$ 419 M	USA
Aeglea BioTherapeutics AGLE	-210 M	-	-	$ 1.01 B	USA
CureVac N.V. CVAC	-412 M	-	-	$ 867 M	Germany
Denali Therapeutics DNLI	-487 M	$ 21.23	5.26 %	$ 3.49 B	USA
Longeveron LGVN	-23.3 M	$ 0.95	-3.52 %	$ 16.7 B	USA
Akero Therapeutics AKRO	-285 M	-	-	$ 3.67 B	USA
Arbutus Biopharma Corporation ABUS	-78.1 M	$ 4.3	1.3 %	$ 714 M	Canada
Akouos AKUS	-86.8 M	-	0.23 %	$ 488 M	USA
AIkido Pharma AIKI	-11.5 M	-	1.93 %	$ 17.4 M	USA